PRGN-3005
Precigen therapeutics
['ovarian', '$pgen']
#asco23: #precigen announces positive phase 1 data for prgn-3005 autologous ultracar-t manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. view press release: #oncology #oncoalert #ovariancancer $pgen 
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies.